FDx Advisors Inc. Has $287,000 Stock Holdings in Gilead Sciences, Inc. $GILD

FDx Advisors Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,591 shares of the biopharmaceutical company’s stock after selling 507 shares during the period. FDx Advisors Inc.’s holdings in Gilead Sciences were worth $287,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GoalVest Advisory LLC raised its stake in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Activest Wealth Management increased its holdings in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences in the 2nd quarter valued at $27,000. Putney Financial Group LLC lifted its holdings in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Colonial Trust Advisors boosted its position in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. UBS Group increased their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Citigroup increased their target price on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Finally, Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $127.82.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 71,500 shares of company stock worth $8,336,040 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Down 3.7%

NASDAQ GILD opened at $118.84 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market cap of $147.46 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 0.81 and a beta of 0.32. The company has a 50 day moving average of $116.49 and a 200-day moving average of $112.22. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.